

TABLE 9.1
Schizophrenia Outcomes:
Developing vs. Developed Countries

	Developing Countries	Developed Countries
Drug Use		
On antipsychotic medication 76% to 100% of follow-up period	15.9%	61%
Best Possible Outcomes		
Remitting course with full remission	62.7%	36.9%
In complete remission 76% to 100% of follow-up period	38.3%	23.3%
Unimpaired <i>basically recovered</i>	42.9%	31.6%
Worst Possible Outcomes		
Continuous episodes without complete remission	21.6%	38.3%
In psychotic episodes for 76% to 100% of follow-up period	15.1%	20.2%
Impaired social functioning throughout follow-up period	15.7%	41.6%

SOURCE: *Psychological Medicine*, supplement 20 (1992)

Courtenay Harding, a psychologist at the University of Colorado, reported on the long-term outcomes of eighty-two chronic schizophrenics discharged from Vermont State Hospital in the late 1950s. She had found that one-third of this cohort had recovered completely. And as she made clear in subsequent publications, the patients in this best-outcomes group shared one common factor: They *all* had successfully weaned themselves from neuroleptics. Hers was the best, most ambitious long-term study that had been conducted in the United States in recent times. The notion that

schizophrenics need concluded, was a ".

The correlation clearly fit with all the drugs. They i akin to that cause gica. They destabil patients more vul: sia, an often irrev age of patients. F term, maintenan people function

cent into psych ken—and by tha you are breaking of social work at

The WHO stu can psychiatry t challenged Ame the disorder. Tl phrenia was no where patients v tions. The WHO belief that schizop disorder, and th was a chance f other countries

who had the n was possible. T the most thera sign themsel: ons. And wit are of the sev them live me posed to neur encourage from neurole